Boston Scientific Corporation

LSE:0HOY Stock Report

Market Cap: US$133.3b

Boston Scientific Valuation

Is 0HOY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HOY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0HOY ($90.25) is trading above our estimate of fair value ($85.84)

Significantly Below Fair Value: 0HOY is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HOY?

Key metric: As 0HOY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0HOY. This is calculated by dividing 0HOY's market cap by their current earnings.
What is 0HOY's PE Ratio?
PE Ratio74.3x
EarningsUS$1.79b
Market CapUS$133.31b

Price to Earnings Ratio vs Peers

How does 0HOY's PE Ratio compare to its peers?

The above table shows the PE ratio for 0HOY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.4x
SN. Smith & Nephew
35.8x22.5%UK£8.6b
NIOX NIOX Group
22.9x17.1%UK£252.3m
SYK Stryker
41.3x11.4%US$148.2b
MDT Medtronic
25.4x10.1%US$109.0b
0HOY Boston Scientific
74.3x23.2%US$133.3b

Price-To-Earnings vs Peers: 0HOY is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the peer average (31.9x).

Price to Earnings Ratio vs Industry

How does 0HOY's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0HOY 74.3xIndustry Avg. 28.9xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0HOY is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the European Medical Equipment industry average (28.9x).

Price to Earnings Ratio vs Fair Ratio

What is 0HOY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HOY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio74.3x
Fair PE Ratio54.6x

Price-To-Earnings vs Fair Ratio: 0HOY is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the estimated Fair Price-To-Earnings Ratio (54.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HOY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$90.75
US$97.00
+6.9%
6.4%US$110.00US$83.00n/a31
Nov ’25US$83.90
US$96.03
+14.5%
6.8%US$110.00US$79.21n/a31
Oct ’25US$83.50
US$87.51
+4.8%
5.4%US$100.00US$78.00n/a32
Sep ’25US$81.09
US$87.17
+7.5%
5.4%US$100.00US$78.00n/a32
Aug ’25US$74.79
US$87.10
+16.5%
5.5%US$100.00US$78.00n/a31
Jul ’25US$76.35
US$82.35
+7.9%
6.3%US$90.00US$70.00n/a31
Jun ’25US$74.69
US$82.06
+9.9%
6.1%US$90.00US$70.00n/a31
May ’25US$72.25
US$80.80
+11.8%
5.7%US$90.00US$70.00n/a32
Apr ’25US$68.75
US$71.73
+4.3%
5.8%US$81.00US$61.00n/a31
Mar ’25US$67.30
US$71.29
+5.9%
6.6%US$81.00US$55.00n/a30
Feb ’25US$64.73
US$69.67
+7.6%
7.5%US$81.00US$55.00n/a30
Jan ’25US$57.96
US$61.62
+6.3%
7.1%US$77.00US$52.50n/a30
Dec ’24US$56.13
US$60.12
+7.1%
4.9%US$67.00US$52.50n/a30
Nov ’24US$51.69
US$59.98
+16.0%
4.8%US$67.00US$52.50US$83.9030
Oct ’24US$53.11
US$60.80
+14.5%
4.5%US$66.00US$55.00US$83.5030
Sep ’24US$53.52
US$59.86
+11.9%
3.9%US$64.00US$55.00US$81.0930
Aug ’24US$51.61
US$59.61
+15.5%
5.8%US$64.00US$45.00US$74.7931
Jul ’24US$53.96
US$58.13
+7.7%
5.6%US$64.00US$45.00US$76.3530
Jun ’24US$51.68
US$57.55
+11.4%
5.5%US$62.00US$45.00US$74.6929
May ’24US$52.70
US$56.92
+8.0%
6.3%US$62.00US$45.00US$72.2527
Apr ’24US$49.83
US$52.89
+6.1%
6.1%US$59.00US$45.00US$68.7527
Mar ’24US$46.87
US$52.51
+12.1%
6.3%US$59.00US$45.00US$67.3027
Feb ’24US$46.80
US$51.46
+10.0%
6.0%US$56.00US$45.00US$64.7326
Jan ’24US$46.10
US$49.75
+7.9%
5.9%US$55.00US$45.00US$57.9628
Dec ’23US$46.06
US$48.65
+5.6%
4.4%US$53.00US$45.00US$56.1326
Nov ’23US$42.70
US$48.64
+13.9%
4.9%US$53.00US$45.00US$51.6926

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.05

7D

-4.2%

1Y

4.8%

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.52

7D

-5.4%

1Y

-8.8%

Guerbet

€335.4m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€26.70

7D

-9.6%

1Y

50.0%